- Stanozolol treatment for successful prevention of attacks of severe primary cryofibrinogenemia.
Stanozolol treatment for successful prevention of attacks of severe primary cryofibrinogenemia.
Pediatric blood & cancer (2010-03-09)
Sule Unal, Fehime Kara, Seza Ozen, Diclehan Orhan, Murat Tuncer, Fatma Gumruk
PMID20209649
摘要
Severe essential cryofibrinogenemia is rare in childhood, and both the diagnosis and the management are challenging for pediatricians. An 11-year-old male, who had already lost two digits following cold exposure, was referred after multiple visits to various hospitals and subsequently diagnosed as primary cryofibrinogenemia. His history revealed unresponsiveness to calcium channel blockers, acetyl salicylic acid, pentoxifylline, dextran, and steroids. Stanozolol (2 mg/day, orally) prophylaxis was initiated and no new skin lesions developed following starting this treatment. Some of the newly formed lesions at the onset of stanozolol healed.
材料
產品編號
品牌
產品描述
Supelco
司坦唑醇 溶液, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material, Cerilliant®